MyoKardia Inc. (NASDAQ:MYOK)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $20.00 and last traded at $18.54, with a volume of 48,795 shares changing hands. The stock had previously closed at $18.59.

Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered MyoKardia from a “hold” rating to a “sell” rating in a report on Friday. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of MyoKardia in a report on Tuesday. BMO Capital Markets assumed coverage on MyoKardia in a report on Wednesday, July 20th. They set an “outperform” rating and a $28.00 price objective for the company. Credit Suisse Group AG reissued a “buy” rating and set a $20.00 price objective (up from $16.00) on shares of MyoKardia in a report on Tuesday, July 12th. Finally, Cowen and Company reissued a “buy” rating on shares of MyoKardia in a report on Friday, May 13th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $23.50.

The stock has a 50 day moving average of $15.62 and a 200-day moving average of $11.85. The company’s market cap is $514.86 million.

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $3.55 million for the quarter, compared to analyst estimates of $3.55 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. Analysts forecast that MyoKardia Inc. will post ($1.54) EPS for the current year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.